LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company’s common shares to a new employee on November 2, 2026. (“Grant”).

The Grant was offered as material inducement to the employee’s employment. The Grant was approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grant was made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08.

The Company is issuing this press release pursuant to Rule 303A.08. The Grant shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.

About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).

ADC Therapeutics’ CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.

Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: whether Tanabe’s marketing authorization application filed with Japan’s Ministry of Health for ZYNLONTA will be accepted, the timing and potential approval of the marketing authorization application for ZYNLONTA in Japan, the timing and payment of future regulatory and commercial milestones related to Japan, Nippon Shinyaku ability to successfully commercialize ZYNLONTA in Japan and the amount of future revenue in Japan and related payments to ADCT; the adequacy of the LOTIS-5 clinical trial data to support full regulatory approval and our ability to maintain accelerated approval in the United States and foreign jurisdictions for our product; our ability to identify and execute on potential regulatory and compendia pathways; the timing, content and outcome of meetings with and feedback or other communications provided by regulatory authorities including U.S. FDA including our ability to adequately address the serious concerns related to the LOTIS-5 trial results raised by the FDA at the recent pre-sBLA submission meeting; the timing, submission and outcome of an sBLA related to LOTIS-5 and potential approval; the actual and perceived benefit-risk profile for ZYNLONTA as studied in the LOTIS-5 trial; the assessment of the data from LOTIS-5 study, including additional analyses of outcomes observed for safety, efficacy and within key geographic regions and across certain patient sub-populations; the path for full regulatory approval for ZYNLONTA in the United States and foreign jurisdictions and into earlier lines of therapy; whether future LOTIS-7 results will be consistent with or different from the prior disclosure, the timing, results and publication of the full LOTIS-7 trial data and potential compendia inclusion; future regulatory strategy for a Phase 3 trial for the combination of ZYNLONTA plus glofitamab; our expected revenue growth in 2027 and the Company’s ability to sustain or grow ZYNLONTA® revenue in the future; our expected cash runway into 2029; changes in our regulatory and commercial strategy; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain or maintain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company’s clinical trials; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company’s products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company’s indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company’s activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities; uncertainties related to a potential change in domicile from Switzerland to Delaware, including the outcome of tax analyses associated with such redomiciliation, the receipt of requisite shareholder approval, and the ability to complete the redomiciliation on the anticipated terms and timeline, if at all; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and in the Company’s other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-announces-new-employee-inducement-grant-302925153.html

SOURCE ADC Therapeutics SA

NEW YORK, Nov. 2, 2026 /PRNewswire/ — People Incorporated (NASDAQ: PPLI) posted its third quarter financial results on its website at https://ir.people-incorporated.com/financials/quarterly-results. As announced previously, People Incorporated will host a conference call to discuss the company’s third quarter results and to answer questions. The call will be held on Tuesday, November 3rd, 2026, at 8:30 a.m. EST. Barry Diller, Chairman and Senior Executive of People Incorporated, Neil Vogel, CEO of People Incorporated, and Tim Quinn, CFO of People Incorporated, will participate.

The live audiocast and replay will be open to the public on People Incorporated’s website at https://ir.people-incorporated.com/quarterly-results.

About People Incorporated
People Incorporated (NASDAQ: PPLI) is the owner of People Inc., the largest digital and print publisher in America and home to more than 40 celebrated brands including PEOPLE, Food & Wine, Travel + Leisure, InStyle, Better Homes & Gardens, and Southern Living, attracting more than 175 million consumers each month. The company also holds a significant minority stake in MGM Resorts International, reflecting our belief in the power and potential of businesses built around enduring consumer brands and iconic, real-world experiences. People Incorporated represents the latest evolution in a long tradition of entrepreneurial ownership, disciplined capital allocation, and opportunistic value creation. Over three decades, the company has built, operated, invested in, and spun off many of the internet and media industry’s defining businesses, and that same spirit of opportunism drives us today. People Incorporated is headquartered in New York City. Visit ir.people-incorporated.com.

Contacts:

People Incorporated Investor Relations
Mark Schneider
 (212) 314-7400

People Incorporated Corporate Communications
Valerie Combs
 (212) 314-7251

View original content:https://www.prnewswire.com/news-releases/people-incorporated-earnings-release-available-on-companys-website-302926683.html

SOURCE People Incorporated

Tinder Daily Active Users Returned to Year-over-Year (“Y/Y”) Growth In September After More Than Three Years

Hinge Delivered Double-Digit User, Revenue, and Payer Growth Y/Y

LOS ANGELES, Nov. 2, 2026 /PRNewswire/ — Match Group (NASDAQ: MTCH) today announced financial results for the third quarter ended September 30, 2026.

“For the past year, we’ve said better user experiences will drive better business results. While there’s still work ahead, Q3 provided more proof points that this strategy is working,” said CEO Spencer Rascoff. “Tinder’s Sparks1 and Sparks Coverage2 delivered their strongest quarterly Y/Y performance since we began tracking them, and Daily Active Users returned to Y/Y growth in September for the first time in three and a half years. The early results from Events and Group Hangouts show Tinder is building the right features, and we’re doubling down on our ‘Better with Friends’ Roadmap to drive reconsideration. Hinge is a leader in intentional dating, and we see significant opportunities ahead in both its core and expansion markets. There is more to do, but we’re delivering on the milestones we set, and our confidence is building as we head into 2027.”

“We delivered against our financial expectations this quarter, while the underlying trends at Tinder continued to improve,” said CFO Steve Bailey. “Our disciplined approach to capital allocation has reduced diluted shares outstanding3 by 4% Y/Y4, and 10% since the beginning of 2025. Looking ahead, we’re focused on translating Tinder’s improving user trends into sustainable revenue growth in 2027, while continuing to deliver strong Free Cash Flow and shareholder return to shareholders.”

Dividend Declaration

Match Group’s Board of Directors has declared a cash dividend of $0.20 per share of the company’s common stock. The dividend is payable on January 21, 2027 to shareholders of record as of January 6, 2027.

Webcast and Prepared Remarks

A webcast of our third quarter 2026 results will be available at https://ir.mtch.com, along with our Prepared Remarks and Supplemental Financial Materials. The call will begin with brief remarks followed by a question and answer session. The webcast will begin today, November 2, 2026, at 5:00 PM Eastern Time.

About Match Group

Match Group is leading the next chapter of human connection. Our global portfolio of brands — including Tinder, Hinge, Match, Pairs, BLK, Upward, OurTime, The League, HER, Azar, and more — sparks meaningful real-world connections across cultures, communities, and every stage of life. Learn more at www.mtch.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

This press release and our webcast, which will be held at 5:00 PM Eastern Time on November 2, 2026, may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are “forward-looking statements.” The use of words such as “anticipates,” “estimates,” “expects,” “plans,” “believes,” “will,” and “would,” among others, generally identify forward-looking statements. These forward-looking statements include, among others, statements relating to: Match Group’s future financial performance, Match Group’s business prospects and strategy, anticipated trends, and other similar matters. These forward-looking statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Actual results could differ materially from those contained in these forward-looking statements for a variety of reasons, including, among others: failure to retain existing users or add new users, or if users do not convert to paying users; competition; risks related to our restructuring and reorganization activities; our ability to attract and retain users through cost-effective marketing efforts; our reliance on a variety of third-party platforms, in particular, mobile app stores; our ability to realize reductions in in-app purchase fees; inappropriate actions by certain of our users could be attributed to us or may not be adequately prevented by us; dependence on our key personnel; volatile global economic conditions; operational and financial risks in connection with acquisitions; impairment charges related to our intangible assets; operations in various international markets, including certain markets in which we have limited experience; foreign currency exchange rate fluctuations; challenges in measuring our user metrics and other estimates; the limited operating history of our newer brands and services makes it difficult to evaluate our current business and future prospects; impacts of climate change; the integrity of our and third parties’ systems and infrastructure; cyberattacks on our systems and infrastructure and cyberattacks experienced by third parties; our ability to access, collect, and use personal data about our users; breaches or unauthorized access of personal and confidential or sensitive user information that we maintain and store; challenges with properly managing the use of artificial intelligence; risks related to credit card payments; risks related to our use of “open source” software; complex and evolving U.S., foreign, and international laws and regulations; our ability to protect our intellectual property rights or accusations that we infringe upon the intellectual property rights of others; adverse outcomes in litigation; risks related to our taxation in multiple jurisdictions; risks related to our indebtedness; and risks relating to ownership of our common stock. Certain of these and other risks and uncertainties are discussed in Match Group’s filings with the Securities and Exchange Commission. Other unknown or unpredictable factors that could also adversely affect Match Group’s business, financial condition and results of operations may arise from time to time. In light of these risks and uncertainties, these forward-looking statements may not prove to be accurate. Accordingly, you should not place undue reliance on these forward-looking statements, which only reflect the views of Match Group management as of the date of this press release. Match Group does not undertake to update these forward-looking statements.

1 Sparks is the number of users engaging in six-way conversations at a brand level in a given week.

2 Sparks Coverage is the percentage of active users at a brand level who experience a Spark in a given period.

3 As defined on page 19 of Match Group’s Q3 2026 Prepared Remarks.

4 As of October 31, 2026.

View original content to download multimedia:https://www.prnewswire.com/news-releases/match-group-announces-third-quarter-results-302926778.html

SOURCE Match Group